Objectives: Screening for cervical intraepithelial neoplasia (CIN) in HIV-infected women is essential to prevent invasive cervical cancer. Visual inspection with acetic acid (VIA) and HPV DNA testing have been proposed as alternatives to traditional cytology (or Papanicolaou [Pap] smears) screening programs. This meta-analysis provides pooled data on test performance (i.e., sensitivity, specificity, positive predictive value, and negative predictive value) of Pap, VIA, and HPV DNA testing with the Hybrid Capture II in HIV-infected women for diagnosing CIN2 or worse (CIN2+). Methods: A meta-analysis of cervical cancer screening test performance for HIV-infected women was conducted following the PRISMA guidelines using PubMed and EMBASE databases. Relevant data were extracted from the articles and analyzed using STATA 13. Results: Six studies met the inclusion criteria and were selected for analysis. The pooled sensitivity of HPV DNA testing was 86.9% (95% CI, 58.3%-97.0%), VIA was 77.6% (95% CI, 73.5%-81.1%), Pap (at a low-grade squamous intraepithelial lesion [LSIL] threshold) 72.8% (95% CI, 41.1%-91.2%) and Pap (at a high-grade SIL [HSIL] threshold) 34.2% (95% CI, 8.7%-74.0%). The pooled specificities were 60.2% (95% CI, 40%-77.5%) for HPV DNA testing, 73.4% (95% CI, 50.5%-88.2%) for VIA, 72.9% (95% CI, 31.6%-94.0%) for Pap (LSIL threshold) and 94.5% (95% CI, 78.0%-98.8%) for Pap (HSIL threshold). Conclusions: HPV DNA screening is a highly sensitive screening technique for HIV-infected women; however, there are still many barriers to its implementation in low-resource settings. VIA-based screening programs are a feasible alternative for HIV-infected women until the required resources (monetary resources and laboratory infrastructure) are committed for HPV DNA based screening programs.